In one paragraphArticle in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Maria G MasengInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0003-3053-0267 Simen H HansenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0003-0156-9875 Olle GrännöDepartment of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, 701 82, Sweden.
Corinna BangInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, 24118 Kiel, Germany.ORCID 0000-0001-6814-6151 Charlotte LundInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0009-0006-5348-4645 Gert Huppertz-HaussDepartment of Gastroenterology, Telemark Hospital Trust, Skien, 3710 Skien, Norway.ORCID 0000-0002-5693-8773 Jørgen ValeurInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0001-7193-7069 Randi OpheimDepartment of Gastroenterology, Division of Medicine, Oslo University Hospital, 0450 Oslo, Norway.ORCID 0000-0002-0513-1435 Svein O FrigstadDepartment of Medicine, Bærum Hospital, Vestre Viken Hospital Trust, 1346 Gjettum, Norway.ORCID 0000-0001-7841-608X Tone Bergene AabrekkInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.
Trond Espen DetlieInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0002-1576-5298 Vendel A KristensenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.
Vibeke StrandeInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0009-0004-9121-6807 Øistein HovdeInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0003-4662-4153 Øyvind AsakDepartment of Medicine, Lillehammer Hospital, Innlandet Hospital Trust, 2609 Lillehammer, Norway.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, 24118 Kiel, Germany.ORCID 0000-0003-1530-5811 Jonas HalfvarssonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, 70182 Örebro, Sweden.ORCID 0000-0003-0122-7234 Marte L HøivikInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0002-0104-465X Johannes R HovInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.ORCID 0000-0002-5900-8096 Funding
90569DFGDFG Excellence Cluster 2167 "Precision Medicine in Chronic Inflammation" (PMI) and the DFG Research Unit 5042 "miTarget"Excellence Cluster 2167Foundation DamNordForskNordForsk 90569 to J.H.Norwegian South-Eastern Health AuthoritiesPrecision Medicine in Chronic InflammationRegional Health Authorities South-Eastern Norway 2020066Regional Health Authorities South-Eastern Norway No: 2020066Research Council of Norway 2988039Research Council of Norway 2988039 to MLHResearch Council of Norway 327634Research Council of Norway no: 327634Takeda PharmaceuticalsTakeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, Foundation Dam, and the Norwegian South-Eastern Health AuthoritiesThe IBSEN IIIVinnova 2019-01185Vinnova 2019-01185 to JH
6 · The paper itselfAbstract
BACKGROUND AND
aimDespite the well-established involvement of the gut microbiome in inflammatory bowel disease (IBD), less is known about how the gut microbiome changes over time and how it varies with clinical disease activity and fecal calprotectin (f-calprotectin). To address this gap, we utilized samples from the population-based inception cohort of the Inflammatory Bowel Disease in South-Eastern Norway III (IBSEN III) study.
methodsData and stool samples from study participants with IBD and symptomatic controls were collected at diagnosis and after 3, 6, and 12 months. Microbiome profiling of stool samples was performed targeting the V3-V4 region of the 16S rRNA gene, and a consensus-based approach of mixed models was employed for the longitudinal microbiome analysis.
resultsWe included 1251 samples from 744 patients with ulcerative colitis, 618 samples from 356 patients with Crohn' s disease and 266 samples from 164 symptomatic non-IBD controls. In the IBD population, we observed that levels of f-calprotectin decreased over time, as did the patient-reported disease activity (P < .001). Distinct changes in the gut microbiome of IBD patients were observed throughout the first year, such as increased alpha diversity (P < .001) and significant taxonomic changes.Notably, there was no covariation between the changes in alpha diversity and f-calprotectin or symptom score.
conclusionThe gut microbiome during the first year after IBD diagnosis showed changes that paralleled inflammation and clinical disease activity, albeit without covariation, suggesting that there may be a disease-driving impact of gut microbiome independent of inflammation and inflammation-driven symptoms.
Indexed as
Colitis, UlcerativeCrohn DiseaseGastrointestinal MicrobiomeInflammationInflammatory Bowel DiseasesAdultCase-Control StudiesFecesFemaleHumansLeukocyte L1 Antigen ComplexLongitudinal StudiesMaleMiddle AgedNorwayRNA, Ribosomal, 16SLeukocyte L1 Antigen ComplexRNA, Ribosomal, 16ScalprotectinIBDlongitudinalmicrobiomesymptoms
Identifiers
PMID41966990
PMCPMC13533192
What OpenQuestion holds
Textmetadata
Read underepoch 390